Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
MetaVia ( (MTVA) ) has issued an announcement.
MetaVia Inc., a clinical-stage biotech focused on cardiometabolic diseases, is advancing two lead programs: DA-1726 for obesity and vanoglipel for MASH, supported by extensive global patent portfolios licensed from Dong-A ST. The company’s pipeline is positioned in the high-growth obesity and liver-disease markets, where differentiated mechanisms such as dual-incretin agonism and GPR119 activation are drawing strong investor and strategic interest.
On May 14, 2026, MetaVia reported first-quarter 2026 results and a corporate update, highlighting 48 mg Phase 1 data for DA-1726 showing 9.1% weight loss, improved glucose control and liver benefit over eight weeks with favorable safety. In early 2026, the company dosed the first patient in a 16-week Part 3 Phase 1 titration study of DA-1726, strengthened IP protection for both DA-1726 and vanoglipel, reported positive AI-modeling data for vanoglipel, closed a $9.3 million financing, and ended March with $13.7 million in cash while posting a $3.8 million quarterly net loss.
First-quarter 2026 R&D expenses fell slightly to $2.1 million while G&A rose to $1.9 million, keeping total operating expenses broadly flat at $4.0 million versus a year earlier. With cash expected to fund operations into the fourth quarter of 2026 and key DA-1726 Phase 1 titration data targeted for late 2026, MetaVia is working to schedule an end-of-Phase 2 meeting with the FDA for vanoglipel in MASH, underscoring a pivotal period for its cardiometabolic portfolio.
The most recent analyst rating on (MTVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, persistent losses, and ongoing cash burn with equity erosion) and a strongly bearish technical setup (price below all key moving averages with negative MACD). Offsetting factors include positive recent corporate milestones for DA-1726, but valuation remains hard to support with negative earnings and no dividend.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on cardiometabolic diseases, developing DA-1726 for obesity and vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis. DA-1726 is a dual GLP-1/glucagon oxyntomodulin analogue aiming for superior weight loss, while vanoglipel is a GPR119 agonist targeting key gut peptides for metabolic and liver benefits.
Average Trading Volume: 151,145
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.01M
See more data about MTVA stock on TipRanks’ Stock Analysis page.